Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392

Watchlist Manager
Beijing Wantai Biological Pharmacy Enterprise Co Ltd Logo
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Watchlist
Price: 73.17 CNY 1.96% Market Closed
Market Cap: 92.5B CNY
Have any thoughts about
Beijing Wantai Biological Pharmacy Enterprise Co Ltd?
Write Note

Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Accounts Receivables
ÂĄ3B
CAGR 3-Years
63%
CAGR 5-Years
74%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Accounts Receivables
ÂĄ2.5B
CAGR 3-Years
86%
CAGR 5-Years
49%
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Accounts Receivables
ÂĄ271m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Accounts Receivables
ÂĄ949.9m
CAGR 3-Years
26%
CAGR 5-Years
3%
CAGR 10-Years
25%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Accounts Receivables
ÂĄ25.5B
CAGR 3-Years
43%
CAGR 5-Years
44%
CAGR 10-Years
51%
Imeik Technology Development Co Ltd
SZSE:300896
Accounts Receivables
ÂĄ206.1m
CAGR 3-Years
91%
CAGR 5-Years
87%
CAGR 10-Years
N/A
No Stocks Found

Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Glance View

Market Cap
92.8B CNY
Industry
Biotechnology

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. has emerged as a key player in the Chinese biopharmaceutical landscape, combining innovation with a commitment to improving healthcare outcomes. Founded in 1990, the company specializes in the research, development, manufacturing, and sale of a wide range of vaccines, diagnostic reagents, and biologic drugs. As one of the forefront companies in China's biotech sector, Wantai has leveraged its technological expertise to create products that address significant public health needs, such as viral infections and autoimmune diseases. With a robust pipeline and strong government support, the company positions itself as a critical contributor to the nation's healthcare ecosystem while aligning with global trends in biopharmaceutical development. For investors, Wantai represents an attractive opportunity, particularly as the demand for effective vaccines and diagnostics continues to surge worldwide. The company's recent IPO and strategic partnerships have bolstered its financial standing, providing a solid foundation for future growth. With an expanding portfolio that includes COVID-19 vaccines and innovative therapeutics, Wantai is poised to capitalize on the growing emphasis on preventative medicine and public health. Moreover, the company's commitment to quality and extensive research capabilities create a sustainable competitive advantage that could yield promising returns for investors navigating the evolving biotechnology market.

Intrinsic Value
63.19 CNY
Overvaluation 14%
Intrinsic Value
Price

See Also

What is Beijing Wantai Biological Pharmacy Enterprise Co Ltd's Accounts Receivables?
Accounts Receivables
3B CNY

Based on the financial report for Dec 31, 2023, Beijing Wantai Biological Pharmacy Enterprise Co Ltd's Accounts Receivables amounts to 3B CNY.

What is Beijing Wantai Biological Pharmacy Enterprise Co Ltd's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
74%

Over the last year, the Accounts Receivables growth was -24%. The average annual Accounts Receivables growth rates for Beijing Wantai Biological Pharmacy Enterprise Co Ltd have been 63% over the past three years , 74% over the past five years .

Back to Top